In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
about
Molecular mechanisms of cisplatin resistance in cervical cancerExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesSatraplatin: leading the new generation of oral platinum agentsPhase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma.A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.An update on satraplatin: the first orally available platinum anticancer drug.Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatinPhase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents.Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatinSatraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.Anticancer activity of metal complexes: involvement of redox processes.Clinical and pharmacokinetic evaluation of satraplatin.Biological and therapeutic relevance of nonreplicative DNA polymerases to cancer.Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.Synthesis and cytotoxicity of platinum(II) complexes of a physiologically active carrier histamine.Preclinical antitumor activity of the oral platinum analog satraplatin.DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo.Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.Satraplatin in the treatment of hormone-refractory prostate cancer.Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.Pyridylphosphinate metal complexes: synthesis, structural characterisation and biological activity.Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
P2860
Q26746228-B4695D19-EC7B-41DD-8B3C-0CC4569F1055Q26828930-67596C68-6DF4-4D4F-8B52-1BF510040F69Q28972468-608630E9-DC85-48FE-B9D5-83E25B57F442Q33330193-FBA295F0-700A-43EC-968B-BB70F33686B5Q33336817-5660AC58-04F1-4D35-BE97-321DE190E9C5Q34074919-4F48CF34-0915-422F-A101-8F4134152986Q35007734-F220EAFD-A46A-4450-9A51-6A3483395783Q35118358-FBD45C0B-7A35-405F-BC97-FAD023AD4553Q36079502-F2142703-92A2-45E9-B43F-E8EF0AF37D97Q36135705-D87574A0-8934-4C4B-8303-72F0BB12EB10Q36417757-AF4FCED5-5032-4A02-8414-7C58380207E3Q36619998-97C10B28-E822-4437-9E69-91229FB34602Q36788357-EFD99BA3-B7C8-4EE7-BEDA-3F99A0C08342Q37136248-DA9DDE39-384C-4B08-9A46-2DB5DFF94505Q37833099-A69B76E9-B12B-44FD-A7E0-50673E65E21AQ37958009-FB5A5CCA-D5A6-4F9E-8025-304A0174849DQ38026112-5ED28C6E-15FD-44E9-8852-15F1DA918725Q38764239-82D304D4-410E-4F2F-8EFA-A425EF3E66B9Q40026733-D78851E2-4619-4146-A256-8BC427610650Q40125464-00729D93-0089-478E-9BF7-AC14B0C00580Q41295381-1D5013C3-BCC3-46F2-A42F-E0736FF8E039Q41438308-CED2223D-3FA2-499E-B5D8-B07E3AC78524Q42590267-A57445E6-25EC-41F9-9161-6055830F8891Q43201303-7FA47A30-AC9E-4029-A051-640CBD3E8CDAQ46753215-E7C76A89-31EA-4794-BC00-61E622023A16Q47648261-300DBCD0-70DD-404B-B913-39CCD91F4D75Q49123833-514FE69E-2CBD-4991-B798-60A8A4DC468DQ52984993-BE3CB3DF-4C94-421E-B009-FCEC9FD62CB4Q54185356-E0E4821F-33E1-4507-9639-931A0952CAA1
P2860
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@ast
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@en
type
label
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@ast
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@en
prefLabel
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@ast
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@en
P2093
P2860
P4510
P356
P1476
In vitro platinum drug chemose ...... uired resistance to cisplatin.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1993.322
P407
P577
1993-08-01T00:00:00Z